Shanrong Biotechnology Corp.
SRBT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.15 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | -21.22% | 0.00% |
| EV / EBITDA | 0.00 | -11.68 | -4.37 | -1.11 |
| Quality | ||||
| ROIC | 0.00% | 64.87% | -479.31% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 1.00 | 0.61 | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.12 | 0.23 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |